Cargando…

Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury

Introduction. The HCV infection is a common disease with many chronically infected patients worldwide. So far, the standard therapy of a chronic HCV infection consisted of interferon as single therapy or in combination with ribavirin. After approval of the two protease inhibitors, boceprevir and tel...

Descripción completa

Detalles Bibliográficos
Autores principales: Callau Monje, David, Braun, Niko, Latus, Joerg, Amann, Kerstin, Alscher, Mark Dominik, Kimmel, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147195/
https://www.ncbi.nlm.nih.gov/pubmed/25197586
http://dx.doi.org/10.1155/2014/308729
_version_ 1782332395690655744
author Callau Monje, David
Braun, Niko
Latus, Joerg
Amann, Kerstin
Alscher, Mark Dominik
Kimmel, Martin
author_facet Callau Monje, David
Braun, Niko
Latus, Joerg
Amann, Kerstin
Alscher, Mark Dominik
Kimmel, Martin
author_sort Callau Monje, David
collection PubMed
description Introduction. The HCV infection is a common disease with many chronically infected patients worldwide. So far, the standard therapy of a chronic HCV infection consisted of interferon as single therapy or in combination with ribavirin. After approval of the two protease inhibitors, boceprevir and telaprevir, the standard therapy for patients with genotype 1 changed. In patients with acute kidney injury (AKI) these therapies are not approved and have so far not been evaluated in studies. Case Report. In April 2012, a 58-year-old female was admitted due to a cryoglobulin-positive chronic HCV infection which had been treated with interferon and ribavirin. Currently, the patient was admitted because of severe complications with an acute kidney injury. We treated our patient successfully with a boceprevir based triple therapy. Conclusion. Limited data suggests that a therapy with ribavirin in patients with AKI seems to be safe under close monitoring. Our patient was treated successfully with a protease inhibitor based triple therapy. Nevertheless, it is necessary to plan an interventional study to evaluate the exact risk-benefit profile of triple therapy regimens in patients with AKI and hepatitis C.
format Online
Article
Text
id pubmed-4147195
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41471952014-09-07 Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury Callau Monje, David Braun, Niko Latus, Joerg Amann, Kerstin Alscher, Mark Dominik Kimmel, Martin Case Rep Nephrol Case Report Introduction. The HCV infection is a common disease with many chronically infected patients worldwide. So far, the standard therapy of a chronic HCV infection consisted of interferon as single therapy or in combination with ribavirin. After approval of the two protease inhibitors, boceprevir and telaprevir, the standard therapy for patients with genotype 1 changed. In patients with acute kidney injury (AKI) these therapies are not approved and have so far not been evaluated in studies. Case Report. In April 2012, a 58-year-old female was admitted due to a cryoglobulin-positive chronic HCV infection which had been treated with interferon and ribavirin. Currently, the patient was admitted because of severe complications with an acute kidney injury. We treated our patient successfully with a boceprevir based triple therapy. Conclusion. Limited data suggests that a therapy with ribavirin in patients with AKI seems to be safe under close monitoring. Our patient was treated successfully with a protease inhibitor based triple therapy. Nevertheless, it is necessary to plan an interventional study to evaluate the exact risk-benefit profile of triple therapy regimens in patients with AKI and hepatitis C. Hindawi Publishing Corporation 2014 2014-08-14 /pmc/articles/PMC4147195/ /pubmed/25197586 http://dx.doi.org/10.1155/2014/308729 Text en Copyright © 2014 David Callau Monje et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Callau Monje, David
Braun, Niko
Latus, Joerg
Amann, Kerstin
Alscher, Mark Dominik
Kimmel, Martin
Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury
title Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury
title_full Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury
title_fullStr Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury
title_full_unstemmed Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury
title_short Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury
title_sort successful antiviral triple therapy in a longstanding refractory hepatitis c virus infection with an acute kidney injury
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147195/
https://www.ncbi.nlm.nih.gov/pubmed/25197586
http://dx.doi.org/10.1155/2014/308729
work_keys_str_mv AT callaumonjedavid successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury
AT braunniko successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury
AT latusjoerg successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury
AT amannkerstin successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury
AT alschermarkdominik successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury
AT kimmelmartin successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury